Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts (Journal of Molecular Medicine, 2013)

(untitled) - Kumar, K; Wigfield, S; Gee, H; Devlin, C; Singleton, D; Li, J; Buffa, F; Huffman, M; Sinn, A; Silver, J; Turley, H; Leek, R; et al.